news aktuell GmbH

Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million

Del

(Aachen, Germany) Grünenthal and Shionogi announced today that they have entered into a licensing agreement for Grünenthal’s investigational medicine Resiniferatoxin (“RTX”). Shionogi obtained the exclusive rights to commercialise Grünenthal’s asset in Japan for pain associated with osteoarthritis of the knee.

RTX is currently in Phase III of clinical development for the treatment of patients with moderate to severe pain associated with knee osteoarthritis. Osteoarthritis, a progressive and often painful joint disease, is an indication with high unmet medical need. If approved, RTX could become a well-tolerated, non-opioid therapy option for patients, providing long-lasting pain relief and functional improvement of the affected knee joints.

Under the terms of the agreement, Shionogi will obtain the exclusive commercialisation rights for RTX in Japan for a total consideration of up to $ 525 million plus additional sales based payments. Thereof, Shionogi will pay $ 75 million upon signature, and further milestone payments of $ 70 million prior to regulatory approval. The agreement includes competitive investment commitments for launch and commercialisation. Manufacturing and supply of RTX to Shionogi will be carried out exclusively by Grünenthal.

“RTX is a promising asset for more than 300 million patients worldwide who suffer from osteoarthritis[1] and seek a meaningful non-opioid therapy option”, says Gabriel Baertschi, Chief Executive Officer, Grünenthal. “With their established presence, strong commercial capabilities and wealth of experience in the pain market, Shionogi is our partner of choice to successfully bring RTX to patients in Japan.”

RTX is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist with a well-validated mechanism of action. An ongoing clinical Phase III programme across sites in Europe, the US, Latin America, South Africa and Japan aims to enable marketing approval for the investigational medicine. New drug applications, including Japan, are targeted for 2024, leading to a potential market entry of RTX in 2025. If the outcome of the Phase III programme is positive, Grünenthal intends to explore the potential of RTX for the treatment of osteoarthritis-related pain in other joints beyond the knee. The global osteoarthritis market is expected to grow to approximately $ 11.0 billion in 2025[2]. Japan represents one of the most important markets in Asia, with significant revenue potential for RTX.

About RTX

RTX is an intra-articular injection of resiniferatoxin developed for the treatment of pain in patients with moderate to severe pain associated with knee osteoarthritis. Resiniferatoxin is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist. Its administration can reversibly defunctionalise TRPV1-expressing nociceptors. This may result in long-lasting pain relief. Initial data shows a long-lasting and significant analgesic effect and functional improvements compared to placebo, as well as a favourable safety profile.

About Osteoarthritis

Osteoarthritis (OA) can be defined as a group of distinct but overlapping diseases. They may have different etiologies but similar biological, morphological, and clinical outcomes that affect the articular cartilage, subchondral bone, ligaments, joint capsule, synovial membrane, and periarticular muscles. OA is the most common joint disease in people aged 65 and over. Its etiology is not fully understood, although several related factors include female gender, genetics, metabolism, and excessive mechanical stress. The diagnosis of OA is primarily based on the clinical history and physical examination. The cardinal radiographic features of OA are focal/non-uniform narrowing of the joint space in the areas subjected to the most pressure, subchondral cysts, subchondral sclerosis, and osteophytes.[3]

Osteoarthritis is a joint disease in which the tissues in the joint break down over time. Common symptoms of osteoarthritis include joint pain, stiffness and swelling, as well as changes in how the joint moves and feeling like the joint is loose or unstable. The most commonly affected joints include the knees, hips, hands, neck and lower back. Treatment of osteoarthritis usually includes exercises, maintaining a healthy weight, wearing braces to help with stability, and taking medication, if prescribed.[4] Many patients will ultimately require joint replacement surgery.

About Shionogi

Shionogi & Co., Ltd. is a leading global research-driven pharmaceutical company based in Japan, dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” We have declared that it will focus on psychoneurological diseases and pain as priority diseases as well as infectious diseases and contributed to improving the activities of daily living and quality of life and productivity of people suffering from pain. For more information, please visit https://www.shionogi.com/global/en/contact.html

About Grünenthal

Grünenthal is a global leader in pain management and related diseases. As a science-based, fully-integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2021, Grünenthal employed around 4,500 people and achieved sales of € 1.5 bn.

More information: www.grunenthal.com

Click here for our Grünenthal Report 2021/2022

Follow us on:

LinkedIn: Grunenthal Group

Instagram: grunenthal


[1]
Cieza, A., Causey, K., Kamenov, K., Hanson, S. W., Chatterji, S., & Vos, T. (2020). Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet, 396(10267), 2006-2017.

[2] MarketsAndMarkets Report; Osteoarthritis Therapeutics Market by Anatomy (Knee, Hand), Drug Type (NSAIDs, Analgesics, Corticosteroids), Route of Administration (Parenteral), Distribution Channel (Hospital Pharmacies),Purchasing Pattern (Prescription Drugs) - Global Forecast to 2025; 2020. https://www.marketsandmarkets.com/Market-Reports/osteoarthritis-therapeutics-market-209565994.html

[3] ICD-11 https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f558562409

[4] National Institute of Arthritis and Musculoskeletal and Skin Diseases; What Causes Osteoarthritis, Symptoms & More | NIAMS (nih.gov)

Kontakter

Florian Dieckmann
Head Global Communication
Grünenthal GmbH
52099 Aachen
Phone: +49 241 569-2555
E-mail: Florian.Dieckmann@grunenthal.com

--

Christopher Jansen
Communication Business Partner
Grünenthal GmbH
52099 Aachen
Phone: +49 241 569-1428
E-mail: Christopher.Jansen@grunenthal.com

Om news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

As wholly owned subsidiary of dpa, news aktuell provides business and organizations with effective access to media and consumers. Via the smart tools ots and zimpel, PR content accesses all media formats, including classical print, high click-rate online portals and social networks. In addition, news aktuell publishes all its customers’ PR content on www.presseportal.de, one of the PR portals with the greatest reach in Germany. By this means, all the relevant multipliers are reached globally, from editors, via digital influencers right up to specialist bloggers and interested consumers. news aktuell has been on the market since 1989. The company, with a staff complement of more than 135, has its headquarters in Hamburg. Other offices are in Berlin, Dusseldorf, Frankfurt und Munich.

Følg pressemeldinger fra news aktuell GmbH

Registrer deg med din epostadresse under for å få de nyeste sakene fra news aktuell GmbH på epost fortløpende. Du kan melde deg av når som helst.

Siste pressemeldinger fra news aktuell GmbH

TXOne Networks and Valmet to expand their successful OT/ICS cybersecurity services partnership22.9.2022 09:45:00 CEST | Press release

(Eindhoven/Tampere) – TXOne Networks, a global leader in ICS and industrial IoT (IIoT) security, and Valmet, a leading global developer and supplier of process technologies, automation and services for the pulp, board, paper, tissue, nonwovens, energy, marine and process industries, have announced a partnership. Together they will better equip joint industrial automation customers with the protection they need for today’s vulnerable OT (Operational Technology) environments. The combination of TXOne Networks’s solutions for security inspection, endpoint protection and network defenses with the leading Valmet DNA Distributed Control System (DCS), Valmet IQ Quality Control System (QCS), Machine Vision, Analyzers & Measurements, Valves and Industrial Internet, offers various advantages: It enhances the ability of industrial customers to better protect, respond, and recover from a cybersecurity incident with Valmet’s Cybersecurity Services. As Dr. Terence Liu, CEO of TXOne Networks, explain

The UAE Country of Honor at Thessaloniki International Fair TIF 86: Minister of Economy Heads UAE’s Delegation to Greece with Extensive Government & Private-Sector Participation9.9.2022 09:11:41 CEST | Pressemelding

Abu Dhabi – 07/09/2022, - Picture is available at AP Images (http://www.apimages.com) - The United Arab Emirates (UAE) will participate — with a high-ranking delegation headed by the UAE Minister of Economy, H.E. Abdulla Bin Touq Al Marri — in the Thessaloniki International Fair TIF 86, which will be held in Greece from 10 to 18 September 2022. The UAE will serve as the Country of Honor at the 86th Thessaloniki International Fair (TIF) in Greece, participating with a prominent delegation that comprises 60 government and private-sector entities. The delegation will showcase the country’s important economic developments, the latest UAE technology-related products, and the nation’s new economic sectors. The UAE’s participation in TIF 86 comes in the context of the nation’s pursuit of attracting USD 150 billion in inward foreign investment over the next 9 years to become one of the top 10 global investment destinations — particularly in the New Economy sectors — by 2030. The UAE’s particip

European news agencies reinforce Brussels reporting with the launch of the European newsroom7.9.2022 08:46:23 CEST | Pressemelding

The European Newsroom (enr), a joint project of 18 European news agencies, was launched in Brussels today. The aim of the initiative is to reinforce reporting from the heart of Europe, as well as fostering cooperation between international agency correspondents. The European Newsroom provides shared workspaces, technical infrastructure and an extensive programme of training and events. In the presence of Commission Vice-Presidents Vera Jourova and Margaritis Schinas, as well as around 200 guests from politics, business and the media, the initiators stressed the importance of international cooperation in the media sector and common efforts to fight disinformation. “The correspondents of the European news agencies require optimal working conditions in the political heart of the continent,” said Peter Kropsch, CEO of dpa. “In Brussels, regulations are initiated that directly affect many millions of people. Not only in the EU member states, but also in the candidate countries. It is theref

I vårt presserom finner du alle våre siste pressemeldinger, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom